Art Unit:

Examiner:

To be determined

To be determined

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Paul J. Coleman

Attorney Docket No.

21442P

PCT Appl. No.:

PCT/US04/025856 Filed: 09 August 2004

Filing Date:

February 7, 2006

For:

MITOTIC KINESIN INHIBITORS

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

LETTER

Sir:

In compliance with 37 C.F.R. 1.821(f) of the Rules of Practice In Patent Cases: Application Disclosures Containing Nucleotide And/Or Amino Acid Sequences, the signature page and following statement are being submitted herewith.

I hereby state that the content of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 C.F.R. 1.821(c) and (e), respectively, are the same.

The enclosed diskette contains the Sequence Listing for case number 21442P.

Respectfully submitted,

Bv:

David A. Muthard Registration No. 35,297 Attorney for Applicants

Merck & Co., Inc. P.O. Box 2000 – RY 60-30 Rahway, New Jersey 07065-0907 Telephone No. (732) 594-3903

Date: February 7, 2006